Bayesian Capital Management, LP Immuno Gen, Inc. Transaction History

Bayesian Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $853,854 - $1.2 Million	60,600 Added 69.91%	147,282 $2.34 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $325,057 - $1.74 Million	86,682 New	86,682 $1.64 Million
Q2 2021 Aug 13, 2021	SELL	$5.79 - $8.6 $57,900 - $86,000	-10,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$6.5 - $10.53 $65,000 - $105,300	10,000 New	10,000 $81,000
Q3 2020 Nov 12, 2020	SELL	$3.45 - $4.89 $42,780 - $60,635	-12,400 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$3.32 - $5.34 $96,612 - $155,394	-29,100 Reduced 70.12%	12,400 $57,000
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $87,980 - $282,200	41,500 New	41,500 $142,000
Q2 2019 Aug 13, 2019	SELL	$1.8 - $3.3 $34,308 - $62,898	-19,060 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$2.41 - $5.91 $45,934 - $112,644	19,060 New	19,060 $52,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.